Krystal Biotech’s Promising Future: Buy Rating Backed by EU Approval and Strategic Market Expansion

William Blair analyst Sami Corwin has maintained their bullish stance on KRYS stock, giving a Buy rating today.

Sami Corwin has given his Buy rating due to a combination of factors that highlight Krystal Biotech’s promising future. The recent marketing authorization of Vyjuvek in the European Union is a significant milestone, as it expands the treatment’s accessibility and potential patient base. The EU approval allows for at-home administration, which is a notable advantage, considering the high preference for home treatment among DEB patients in the U.S.
Furthermore, Krystal Biotech’s strategic plans for launching Vyjuvek in Germany and France, along with preparations in Japan, indicate a robust commercial strategy aimed at capturing a substantial market share. The company’s goal to penetrate 60% of the DEB patient population in France and Germany within two years underscores its growth potential. Additionally, the possibility of expanding the U.S. label to include younger patients and at-home administration could further enhance Vyjuvek’s market appeal. These factors collectively suggest a strong revenue outlook, with projections of significant earnings by 2025, thereby justifying the Buy rating.

In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $240.00 price target.